Core Viewpoint - NKGen Biotech is advancing its Phase 1/2a clinical trial for troculeucel, a novel NK cell therapy for moderate Alzheimer's disease, by activating two additional clinical trial sites in Canada and the U.S. to enhance patient recruitment and diversity [1][2][4]. Group 1: Clinical Trial Updates - NKGen has activated two new clinical trial sites: Ottawa Memory Clinic in Canada and AdventHealth Orlando in Florida, USA, which are now open for patient enrollment [1][2]. - The activation of these sites is crucial for initiating patient recruitment and ensuring the trial progresses as planned [1]. - The Ottawa Memory Clinic is recognized for its expertise in Alzheimer's research and will play a significant role in the trial for Canadian patients [2][3]. Group 2: Leadership and Expertise - Dr. Richard Bergeron, a prominent neuroscientist with extensive experience in neurodegenerative disease research, will lead the Ottawa Memory Clinic site [3][6]. - Dr. Bergeron has overseen over 60 clinical trials and is known for his work in both disease-modifying and symptomatic treatments for Alzheimer's disease [3][6]. - NKGen's CEO, Dr. Paul Y. Song, emphasized the importance of Dr. Bergeron's expertise in expanding patient access to troculeucel and achieving enrollment goals [4]. Group 3: Product Information - Troculeucel is an innovative, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate being developed for neurodegenerative disorders and various cancers [5]. - The World Health Organization has assigned the International Nonproprietary Name (INN) "troculeucel" to SNK01, marking a significant milestone in NKGen's development journey [5]. Group 4: Company Overview - NKGen Biotech is a clinical-stage biotechnology company headquartered in Santa Ana, California, focused on developing and commercializing NK cell therapeutics [8][9].